A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
Status:
Completed
Trial end date:
2021-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if treatment with NEO-PV-01 in combination with
pembrolizumab and chemotherapy (pembrolizumab/chemotherapy) is safe and useful for patients
with lung cancer. The study also will assess if the NEO-PV-01 vaccine, when given together
with pembrolizumab and chemotherapy, can improve your response compared with pembrolizumab
and chemotherapy treatment alone. All eligible patients will receive NEO-PV-01 + Adjuvant,
pembrolizumab and chemotherapy while on this trial.